



(51) International Patent Classification:

A61K 35/76 (2015.01) C12N 15/86 (2006.01)
C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2020/015021

(22) International Filing Date:

24 January 2020 (24.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/796,575 24 January 2019 (24.01.2019) US

(71) Applicant: **UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.** [US/US]; 12201 Research Parkway, Suite 501, Orlando, Florida 32826 (US).


(72) Inventors: **COPIK, Alicja**; 4365 Andromeda Loop N., Orlando, Florida 32816 (US). **PARKS, Griffith**; 4365 Andromeda Loop N., Orlando, Florida 32816 (US). **OYER, Jeremiah**; 4365 Andromeda Loop N., Orlando, Florida 32816 (US).

(74) Agent: **LANIER, J. Gibson** et al.; 999 Peachtree St. NE, Suite 1300, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR STIMULATING NATURAL KILLER CELLS



(57) Abstract: Compositions and methods for stimulating NK cell expansion and cytotoxicity are described. Therapeutic compositions and methods using expanded and stimulated NK cells are described.

[Continued on next page]

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*